PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Evan A. Stein et al.|The Lancet|2014Cited by 750
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Ioanna Gouni‐Berthold et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595
Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 DiabetesIoanna Gouni‐Berthold, Wilhelm Krone, Heiner K. Berthold et al.|Diabetes Care|2008Cited by 189
Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex VivoIoanna Gouni‐Berthold, Christos S. Mantzoros, Joo Young Huh et al.|PLoS ONE|2013Cited by 139